A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: people (1000), residents (55)

Joint Partnership Policy and Guidance on Pre-clinical and Clinical Research Publications

Description
Joint Partnership Policy and Guidance on Pre-clinical and Clinical Research Publications ? ? ? ? Background Scope: who this policy and guidance applies to Policy statem
Url
/Media/Southampton-Clinical-Research/Downloads/Joint-Partnership-Policy-and-Guidance-on-Pre-clinical-and-Clinical-Research-Publications.pdf

NIHR expression of interest

Description
NIHR CRN Site Identification Support Expression of Interest (EOI) Guidance (v2 May 2018) The expression of interest process is intended to facilitate the rapid id
Url
/Media/Southampton-Clinical-Research/NIHR-expression-of-interest.pdf

Procedure for adult height

Description
NIHR Southampton Biomedical Research Centre The NIHR Southampton Biomedical Research Centre (BRC) has a tight quality assurance system for the writing
Url
/Media/Southampton-Clinical-Research/Procedures/BRCProcedures/Procedure-for-adult-height.pdf

Ibrutinib-Venetoclax

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia IBRUTINIB-VENETOCLAX Regimen CLL – Ibrutinib & Venetoclax Indication • Ibrutinib
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Ibrutinib-Venetoclax-Ver1.1.pdf

WGLS (combined) user handbook

Description
University Hospital Southampton NHS Foundation Trust DOC987 Revision 1/ WRGL 33687 V1.0 Wessex Genomics Laboratory Service Wessex
Url
/Media/UHS-website-2019/Docs/Services/Pathology/WGLS-combined-user-handbook.pdf

Risk-reducing bilateral salpingo-oophorectomy - patient information

Description
This booklet explains what a risk-reducing bilateral salpingo-oophorectomy is and what the operation involves to help you decide whether
Url
/Media/UHS-website-2019/Patientinformation/Genetics/Risk-reducing-bilateral-salpingo-oophorectomy-1434-PIL.pdf

WRES report and action plan 2023

Description
Workforce Race Equality Standard Annual Report 2023 1 Table of Contents Executive Summary................................................................................................................................. 3 Introduction ............................................................................................................................................ 5 WRES Data Submission 2023 .................................................................................................................. 5
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/WRES-report-and-action-plan-2023.pdf

Breathing pattern disorders - patient information

Description
Breathing pattern disorders are patterns of overbreathing, where the depth and rate of breath are in excess of the body's needs
Url
/Media/UHS-website-2019/Patientinformation/Respiratory/Breathing-pattern-disorders-patient-information.pdf

Cytarabine(SC)-Venetoclax

Description
Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Newly diagnos
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexa
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf
141 to 150 of 185
Previous … 13 14 15 16 17 … Next